{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:33:04Z","timestamp":1771047184273,"version":"3.50.1"},"reference-count":44,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HBV reactivation can occur while undergoing direct\u2010acting antiviral (DAA) therapy for hepatitis C virus (HCV). The role of hepatitis B surface antibody (HBsAb) has not been systematically explored. Therefore, the purpose of this systematic review was to explore the role of the presence of HBsAb on the risk of HBV reactivation related to DAA therapy. We reviewed MEDLINE, CINAHL, EMBASE and Cochrane Central for studies on DAA therapy and data on HBsAb in patients with resolved hepatitis B (hepatitis B surface antigen\u2013negative and hepatitis B core antibody\u2013positive). We identified twenty\u2010nine reports: thirteen case reports with HBV reactivation (10 HBsAb\u2010negative and 3 HBsAb\u2010positive patients) and sixteen cohort studies totalling 2528 patients with resolved HBV infection (1429 HBsAb negative, 1099 HBsAb positive). Reactivation was found in 12 (0.8%) HBsAb\u2010negative and 7 (0.6%) HBsAb\u2010positive individuals of cohort studies. All but two HBV reactivation occurred in patients with HBsAb titre &lt;30 iU\/L. The presence of HBsAb showed a trend towards delayed reactivation (median 12\u00a0weeks vs 9.5\u00a0weeks; <jats:italic>P<\/jats:italic>\u00a0=\u00a0.07). Importantly, with the exception of a patient with escape variant and an HIV\u2010infected individual, no HBsAb\u2010positive individual demonstrated clinical reactivation. HBsAb presence seems to protect from clinical HBV reactivation related to DAA therapy. The most pronounced prevention for reactivation may require titres greater than 30\u00a0iU\/L.<\/jats:p>","DOI":"10.1111\/jvh.13421","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T03:00:05Z","timestamp":1602558005000},"page":"373-382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hepatitis B surface antibody titres and hepatitis B reactivation with direct\u2010acting antiviral therapy for hepatitis C"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8447-2149","authenticated-orcid":false,"given":"Shiva","family":"Poola","sequence":"first","affiliation":[{"name":"Department of Medicine East Carolina University  Greenville NC USA"},{"name":"Department of Medicine Division of Gastroenterology Hepatology &amp; Nutrition East Carolina University  Greenville NC USA"},{"name":"Vidant Medical Center  Greenville NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirish","family":"Sanaka","sequence":"additional","affiliation":[{"name":"Department of Medicine East Carolina University  Greenville NC USA"},{"name":"Department of Medicine Division of Gastroenterology Hepatology &amp; Nutrition East Carolina University  Greenville NC USA"},{"name":"Vidant Medical Center  Greenville NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0405-3789","authenticated-orcid":false,"given":"Kerry","family":"Sewell","sequence":"additional","affiliation":[{"name":"Research Librarian for the Health Sciences East Carolina University  Greenville NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1401-2208","authenticated-orcid":false,"given":"Hans L.","family":"Tillmann","sequence":"additional","affiliation":[{"name":"Department of Medicine East Carolina University  Greenville NC USA"},{"name":"Department of Medicine Division of Gastroenterology Hepatology &amp; Nutrition East Carolina University  Greenville NC USA"},{"name":"Vidant Medical Center  Greenville NC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,11,2]]},"reference":[{"issue":"67","key":"e_1_2_8_2_1","first-page":"370","article-title":"Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"2017","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29135"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0377"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3260"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13496"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12754"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2018.01.118"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)33681-8"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12737"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx028"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2017.05.021"},{"key":"e_1_2_8_14_1","first-page":"1202","article-title":"No evidence of reactivation of hepatitis B virus among patients treated with ledipasvir-sofosbuvir for hepatitis C virus infection","volume":"63","author":"Sulkowski MS","year":"2016","journal-title":"Clin Infect Dis"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12840"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(17)33576-X"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13771"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3259"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy340"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12919"},{"key":"e_1_2_8_21_1","first-page":"129","article-title":"Hepatitis B virus in patients with chronic hepatitis C treated with direct antiviral agents","volume":"111","author":"Guti\u00e9rrez Garc\u00eda ML","year":"2019","journal-title":"Rev Esp Enferm Dig"},{"key":"e_1_2_8_22_1","first-page":"A135","article-title":"Reactivation of hepatitis B virus infection during treatment of hepatitis C with direct-acting antivirals","volume":"6","author":"Figueiredo LM","year":"2018","journal-title":"United Eur Gastroenterol J"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2287-y"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2016.02.026"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.014"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ474"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-015-0630-8"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-016-0657-4"},{"key":"e_1_2_8_29_1","first-page":"218","article-title":"Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection","volume":"40","author":"Odolini S","year":"2017","journal-title":"New Microbiol"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2019.11.018"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2018.11.014"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29528"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.5114\/hivar.2018.76378"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s13256-019-2232-3","article-title":"Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report","volume":"13","author":"Foroghi Biland L","year":"2019","journal-title":"J Med Case Rep"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","unstructured":"MadoniaS OrlandoE the GMOJO.HCV\/HBV coinfection: The dark side of DAAs treatment?.2017.","DOI":"10.1111\/liv.13342"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix659"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.7326\/L17-0477"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30002-5"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1325869"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1748-z"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.023"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-012-1405-6"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)30778-1"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29082"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.02.009"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13421","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13421","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13421","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T04:41:32Z","timestamp":1693543292000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1111\/jvh.13421"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13421","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,2]]},"assertion":[{"value":"2020-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}